Table 1.
Ranibizumab-related adverse events followed 24-month study period.
| Adverse Events at 24 months | Sham injection | Group 0.3 mg | Group 0.5 mg |
|---|---|---|---|
| Endopnthalmitis | 0% | 0.8% | 1.3% |
| Uveitis | 0% | 1.3% | 1.3% |
| Rhegmatogenous retinal detachment | 0.4% | 0% | 0% |
| Retinal tear | 0% | 0.4% | 0.4% |
| Vitreous hemorrhage | 0.8% | 0.4% | 0.4% |
| Lens damage | 0% | 0% | 0.4% |
|
| |||
| Most severe ocular inflammation | |||
| none | 87.3 | 83.2% | 79.1% |
| trace | 10.2 | 8.0% | 14.6% |
| 1+ | 2.5% | 5.9% | 3.3% |
| 2+ | 0 | 0.8% | 0.8% |
| 3+ | 0 | 0.8% | 0.8% |
| 4+ | 0 | 1.3% | 1.3% |
|
| |||
| Nonocular adverse events | |||
|
| |||
| Arterial hypertension | 16.1 | 17.2% | 16.3% |
| Myocardial infarction | 1.7% | 2.5% | 1.3% |
| Stroke | 0.8% | 1.3% | 2.5% |
| Non ocular hemorrhage | 5.5% | 9.2% | 8.8% |